Oncology Solid Tumors
Empowering clinicians to deliver more personalized healthcare
Precision medicine requires precision in clinical interpretation and reporting. With QIAGEN Clinical Insights (QCI) Interpret for Oncology, your lab gains access to the most clinically relevant and up-to-date information, drastically reducing your curation time. The intuitive software produces concise, actionable reports that accelerates your clinicians’ ability to deliver the best treatment options for their patients.
Live Webinar on March 7
Join Dr. Marie-Laure Yaspo, Co-Founder and Chief Scientific Officer of Alacris Theranostics, as she discusses the application and analysis of the Comprehensive Molecular Tumor Analysis (CMTA) using QCI Interpret for Oncology.
Actionable reports for simplified decison-making
QCI nterpret for Oncology interprets a cancer patient’s genetic data, building a personalized report that informs the oncologist of which genetic mutations are likely causing the cancer, which precision therapies are known to work against these mutations, and where the patient can go to access these treatments or trials.
Munich Leukemia Laboratory selects QCI Interpret for NGS solid tumor testing
Munich Leukemia Laboratory, one of the world’s largest leukemia laboratories, has selected QCI Interpret for Oncology to support the analysis, interpretation, and reporting of Illumina’s TruSight Oncology 500 Assay, a comprehensive genomic profiling test for solid tumors.
Solutions for oncology NGS testing
QCI Precision Insights
Professional variant interpretation service for oncology NGS testing
Interested in our multimodal NGS panels?
Learn more about QIAGEN’s QIAseq Multimodal Panels for comprehensive genomic profiling of solid tumors and hematological malignancies.
